{"id":"imipenem-relebactam","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Phlebitis at infusion site"},{"rate":null,"effect":"Seizures (rare, especially with renal impairment)"}]},"_chembl":null,"_dailymed":{"setId":"be32f468-738b-40df-a425-591e12f65159","title":"RECARBRIO (IMIPENEM ANHYDROUS, CILASTATIN, AND RELEBACTAM ANHYDROUS) INJECTION, POWDER, FOR SOLUTION [MERCK SHARP & DOHME LLC]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Imipenem works by binding to penicillin-binding proteins and disrupting peptidoglycan cross-linking in the bacterial cell wall, leading to cell lysis and death. Relebactam inhibits serine beta-lactamases (including class A and C enzymes) that would otherwise inactivate imipenem, thereby restoring imipenem's activity against beta-lactamase-producing resistant organisms. This combination extends imipenem's spectrum to include carbapenem-resistant Enterobacteriaceae and other resistant gram-negative pathogens.","oneSentence":"Imipenem is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis, while relebactam is a beta-lactamase inhibitor that protects imipenem from enzymatic degradation by resistant bacteria.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:48:14.740Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Complicated urinary tract infections (cUTI) caused by susceptible gram-negative bacteria"},{"name":"Hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) caused by susceptible pathogens"}]},"trialDetails":[{"nctId":"NCT03969901","phase":"PHASE2, PHASE3","title":"Safety, Tolerability, Efficacy and Pharmacokinetics of Imipenem/Cilastatin/Relebactam (MK-7655A) in Pediatric Participants With Gram-negative Bacterial Infection (MK-7655A-021)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-10-08","conditions":"Suspected or Documented Gram-negative Bacterial Infection","enrollment":115},{"nctId":"NCT05204563","phase":"PHASE3","title":"Imipenem/Cilastatin-XNW4107 Versus Imipenem/Cilastatin/Relebactam for Treatment of Participants With Bacterial Pneumonia (XNW4107-302, REITAB-2)","status":"COMPLETED","sponsor":"Evopoint Biosciences Inc.","startDate":"2022-07-31","conditions":"Hospital Acquired Bacterial Pneumonia or Ventilator-Associated Bacterial Pneumonia","enrollment":450},{"nctId":"NCT03583333","phase":"PHASE3","title":"Imipenem/Cilastatin/Relebactam (MK-7655A) Versus Piperacillin/Tazobactam in Participants With Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia (MK-7655A-016)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-09-18","conditions":"Hospital-Acquired Bacterial Pneumonia, Ventilator-Associated Bacterial Pneumonia","enrollment":274},{"nctId":"NCT05561764","phase":"PHASE4","title":"Imipenem/Cilastatin/Relebactam Pharmacokinetics, Safety, and Outcomes in Adults and Adolescents With Cystic Fibrosis","status":"TERMINATED","sponsor":"Hartford Hospital","startDate":"2023-01-03","conditions":"Cystic Fibrosis, Pneumonia, Bacterial","enrollment":4},{"nctId":"NCT05146154","phase":"PHASE4","title":"Impact of Obesity on the Pharmacokinetics of Imipenem-Relebactam in ICU Patients","status":"WITHDRAWN","sponsor":"University of Illinois at Chicago","startDate":"2023-01-01","conditions":"Obesity, Critical Illness","enrollment":""},{"nctId":"NCT04983901","phase":"PHASE2","title":"PHASE II SINGLE-CENTER, RANDOMIZED, OPEN-LABEL, PROSPECTIVE, STUDY TO DETERMINE THE IMPACT OF SERIAL PROCALCITONIN","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-09-14","conditions":"Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm","enrollment":100},{"nctId":"NCT04785924","phase":"PHASE4","title":"Imipenem/Cilastatin/Relebactam (IMI/REL) in Treatment of CRE Infections","status":"WITHDRAWN","sponsor":"Wake Forest University Health Sciences","startDate":"2021-06-07","conditions":"Carbapenem-Resistant Enterobacteriaceae Infection, KPC, Gram-Negative Bacterial Infections","enrollment":""},{"nctId":"NCT04493151","phase":"PHASE1","title":"Imipenem/Cilastatin/Relebactam PK in ECMO","status":"COMPLETED","sponsor":"Joseph L. Kuti, PharmD","startDate":"2021-01-01","conditions":"Sepsis","enrollment":8},{"nctId":"NCT04147221","phase":"PHASE1","title":"Imipenem-Relebactam Pharmacokinetics in Augmented Renal Clearance","status":"COMPLETED","sponsor":"Hartford Hospital","startDate":"2020-02-10","conditions":"Sepsis","enrollment":9},{"nctId":"NCT05048693","phase":"","title":"Use of New Antibiotics in Sweden","status":"COMPLETED","sponsor":"Uppsala University","startDate":"2021-11-01","conditions":"Multi-antibiotic Resistance","enrollment":41},{"nctId":"NCT03230916","phase":"PHASE1","title":"A Pharmacokinetics Study of MK-7655A in Pediatric Participants With Gram-negative Infections (MK-7655A-020)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2017-11-06","conditions":"Suspected or Documented Gram-negative Bacterial Infection","enrollment":47},{"nctId":"NCT05285046","phase":"","title":"Phenotypic Profile and Molecular Mechanism of Resistance in Carbapenemase-producing Enterobacterales and Pseudomonas Aeruginosa Isolates From Brazilian Hospitals: Implications for the Introduction of IMIPENEM-RELEBACTAM","status":"UNKNOWN","sponsor":"D'Or Institute for Research and Education","startDate":"2022-04-01","conditions":"Bacterial Infections, Antibiotic Resistant Infection","enrollment":250},{"nctId":"NCT03293485","phase":"PHASE3","title":"Efficacy and Safety of Imipenem+Cilastatin/Relebactam (MK-7655A) in Japanese Participants With Complicated Intra-abdominal Infection or Complicated Urinary Tract Infection (MK-7655A-017)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2017-10-04","conditions":"Complicated Intra-abdominal Infection, Complicated Urinary Tract Infection","enrollment":83},{"nctId":"NCT01275170","phase":"PHASE1","title":"A Single-Dose Study to Investigate the Pharmacokinetics of MK-7655 in Participants With Impaired Renal Function (MK-7655-005)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-01-28","conditions":"Infectious Disease","enrollment":49},{"nctId":"NCT02493764","phase":"PHASE3","title":"Imipenem/Relebactam/Cilastatin Versus Piperacillin/Tazobactam for Treatment of Participants With Bacterial Pneumonia (MK-7655A-014)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-11-24","conditions":"Bacterial Pneumonia","enrollment":537},{"nctId":"NCT04196608","phase":"","title":"In Vitro Activity of Ceftolozane/Tazobactam and Imipenem/Relebactam in Clinical Isolates of Pseudomonas Aeruginosa and Enterobacterales Collected From Hematology and Oncology Patients","status":"UNKNOWN","sponsor":"Emilio Bouza","startDate":"2019-11-01","conditions":"Ceftolozane/Tazobactam, Imipenem/Relebactam, Hematology and Oncology","enrollment":1005},{"nctId":"NCT01506271","phase":"PHASE2","title":"Study of the Safety, Tolerability, and Efficacy of Relebactam (MK-7655) + Imipenem/Cilastatin Versus Imipenem/Cilastatin Alone to Treat Complicated Intra-Abdominal Infection [cIAI] (MK-7655-004)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-06-01","conditions":"Intra-abdominal Infections","enrollment":351},{"nctId":"NCT01505634","phase":"PHASE2","title":"Safety, Tolerability, and Efficacy of MK-7655 (Relebactam) + Imipenem/Cilastatin Versus Imipenem/Cilastatin Alone for Treating Complicated Urinary Tract Infection (cUTI) (MK-7655-003)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-05-16","conditions":"Urinary Tract Infections, Pyelonephritis","enrollment":302},{"nctId":"NCT02452047","phase":"PHASE3","title":"Efficacy and Safety of Imipenem+Cilastatin/Relebactam (MK-7655A) Versus Colistimethate Sodium+Imipenem+Cilastatin in Imipenem-Resistant Bacterial Infection (MK-7655A-013)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-08-21","conditions":"Bacterial Infections","enrollment":50}],"_emaApprovals":[],"_faersSignals":[{"count":16,"reaction":"PSEUDOMONAS INFECTION"},{"count":15,"reaction":"SEPSIS"},{"count":14,"reaction":"PATHOGEN RESISTANCE"},{"count":14,"reaction":"RENAL FAILURE"},{"count":12,"reaction":"DRUG INEFFECTIVE"},{"count":11,"reaction":"NEPHROPATHY TOXIC"},{"count":10,"reaction":"FEBRILE NEUTROPENIA"},{"count":10,"reaction":"THROMBOCYTOPENIA"},{"count":9,"reaction":"OTOTOXICITY"},{"count":8,"reaction":"CELLULITIS"}],"_approvalHistory":[],"publicationCount":411,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Recarbrio"],"phase":"marketed","status":"active","brandName":"Imipenem+Relebactam","genericName":"Imipenem+Relebactam","companyName":"Wake Forest University Health Sciences","companyId":"wake-forest-university-health-sciences","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Imipenem is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis, while relebactam is a beta-lactamase inhibitor that protects imipenem from enzymatic degradation by resistant bacteria. Used for Complicated urinary tract infections (cUTI) caused by susceptible gram-negative bacteria, Hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) caused by susceptible pathogens.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}